INDEMNIFICATION AGREEMENTIndemnification Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of [_____], 2022 , is entered into by and between Regentis Biomaterials Ltd., an Israeli company whose address is 12 Ha’ilan Street, Northern Industrial Zone, P.O. Box 260 Or-Akiva 306000, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page attached hereto (the “Indemnitee”).
AGREEMENTService Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Agreement is entered into as of on December 5, 2022, effective as of March 31, 2022 (the “Commencement Date”), by and between Regentis Biomaterials Ltd., a company incorporated in the State of Israel whose address is 60 Medinat Hayehudim Street, Entrance C. Herzeliya, Israel (the “Company”), and Mr. Noam Band, ID no. [_________], of [______________]., Tel Aviv, Israel (the “Service Provider”).
AMENDED AND RESTATED SUPPLY AGREEMENTSupply Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Delaware
This Amended and Restated Supply Agreement (this “Agreement”) is entered into, effective as of January 6, 2009 (the “Effective Date”) by and between
SERIES B PREFERRED SHARE PURCHASE AGREEMENTSeries B Preferred Share Purchase Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS SERIES B PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is entered into on and as of this 2nd day of August, 2007, by and among (i) Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Company”); (ii) The Technological Incubator Founded by the Technion R&D Foundation Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 510340677, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Incubator”); (iii) Dr. Dror Seliktar of Bio-Medical Engineering Department, Technion, Technion City, Haifa 32000, Israel (“Seliktar”); (iv) Mr. Yehiel Tal of 6 Hamaish Street, Zichron Yaakov, Israel (“Tal”) (Seliktar and Tal each a “Founder” and collectively the “Founders”); and (iv) the investors listed on Schedule A to this Agreement (each, an “Investor” and
SERVICES AGREEMENTServices Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Delaware
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) made as of the 5th day of February 2016, by and among Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at 12 Ha’ilan street, Northern Industrial Zone, P.O.B 260, Or Akiva 30600, Israel(the “Company”), the individuals and entities identified in Schedule 1 attached hereto (collectively, the “Series A Preferred Holders”), the individuals and entities identified in Schedule 2 attached hereto ( the “Series B Preferred Holders”); the individuals and entities identified in Schedule 3 attached hereto (collectively, the “Series C Preferred Holders”), the individuals and entities identified in Schedule 4 attached hereto ( the “Series D Preferred Holders” and together with the Series A Preferred Holders and the Series B Preferred, Series C Preferred the “Preferred Holders”); The Company, the Series A Preferred Holders Series B Preferred Holders the
